Cosan S.A. (CSAN) Stock Price & How to Invest

Cosan S.A. began in 1936 as a sugar mill operator in Sao Paulo state and is now a holding company that sits above several separate Brazilian businesses. Compass distributes natural gas, including Comgas, the country's largest piped-gas utility, and operates the Edge regasification terminal at the Port of Santos. Rumo runs the largest freight rail network in Brazil, hauling grain and sugar to Santos and to northern ports. Moove blends and sells lubricants as the Mobil licensee across Brazil, parts of South America and Europe. Radar holds farmland. Raizen, the roughly 50/50 sugar, ethanol and fuel-distribution joint venture with Shell, was historically the largest piece and is now the source of the group's damage. Cosan employs roughly ~29,000 people, reports in Brazilian reais, and trades in Sao Paulo as CSAN3; one ADS on the NYSE represents one common share.

Leverage is the central fact here, not a footnote. Cosan booked a net loss of roughly ~R$9.7 billion in 2025 driven by impairments at Raizen, and in March 2026 Raizen filed for extrajudicial reorganization, after which Cosan cut the carrying value of that investment to zero and stopped recognizing its results under the equity method. The holding company then spent 2025 and 2026 shrinking its own debt: a capital increase of roughly ~R$10.5 billion, redemption of debentures and offshore bonds, and roughly ~R$6.2 billion of debt repaid, leaving expanded net debt near ~R$11.5 billion at the first quarter of 2026, down about ~34% from a year earlier though up about ~18% sequentially. Management has said the portfolio itself is for sale in pieces: BTG Pactual has a mandate covering part of the roughly ~23% Rumo stake, a secondary offering of Compass shares has been floated, and the roughly ~4.1% holding in iron ore producer Vale is on the table. Against roughly ~$7.6 billion of trailing revenue, the ADR carries a market capitalization near ~$2.8 billion, which is the market pricing the stakes minus the holding debt rather than pricing earnings, since there are none on a trailing basis.

Raizen is the open wound: an extrajudicial reorganization is ongoing, Cosan has said it has no legal or constructive obligation to fund it, and creditors may test that position. Selling the Rumo stake or a Compass tranche into a weak Brazilian market risks realizing prices below the carrying values investors are underwriting, and a failed process leaves the holding debt in place. Brazilian policy rates set the cost of the remaining debt, so any move higher in the Selic rate compresses the equity residual directly, and the reais-denominated results translate into a variable dollar figure for a US holder. The capital increase materially raised the share count to roughly ~3.9 billion shares, so per-share recovery lags any recovery in enterprise value. There is no meaningful dividend while deleveraging is the priority, and analyst consensus sits at Hold with an average target near ~$3.69, which is a wide range around a small price rather than a firm view.

4 analysts publish price targets on CSAN, averaging $3.71 against a $2.88 price as of August 2026, or +28.8%. The published targets run from $3.15 to $4.21, a narrow spread, and the ratings split 1 buy, 2 hold, 1 sell. Over the last six months there have been 0 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CSAN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Cosan S.A.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Deleveraging by divestment rather than by earnings. The debt reduction achieved so far came from a roughly ~R$10.5 billion capital increase and from selling core assets, not from operating cash at the holding level. The most optimistic published target, $4.21, assumes this works close to its best case.

The case against. Raizen is the open wound: an extrajudicial reorganization is ongoing, Cosan has said it has no legal or constructive obligation to fund it, and creditors may test that position. The most pessimistic target, $3.15, is roughly what CSAN is worth if this bites instead.

Read the full bull and bear case on CSAN, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Cosan S.A.'s investor relations page or your broker.

• Revenue (TTM): ~$7.6 billion, reported in Brazilian reais
• Q1 2026 net sales: ~R$9.0 billion, down from ~R$9.7 billion
• Q1 2026 EBITDA: ~R$3.2 billion, up from ~R$2.0 billion
• Q1 2026 net loss: ~R$1.3 billion, narrowed from ~R$1.9 billion
• Expanded net debt: ~R$11.5 billion, down ~34% year over year
• Market capitalization: ~$2.8 billion at a share price near ~$2.88

There is no trailing price-to-earnings figure because Cosan lost roughly ~$1.8 billion (about ~R$9.7 billion) over the last twelve months, mostly on Raizen impairments rather than on operations. Valuation work on CSAN is therefore a sum-of-the-parts exercise: mark Compass, Rumo, Moove and Radar, subtract holding-company debt near ~R$11.5 billion, and assign zero to Raizen as the company itself now does. The next report is scheduled for around ~August 14, 2026.

Other names that sit close to CSAN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CSAN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CSAN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CSAN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

CSAN is a debt-reduction and asset-sale story wrapped around real Brazilian infrastructure, and the equity tracks what Cosan manages to sell rather than what its subsidiaries ship each quarter.

Whether CSAN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CSAN a buy or a sell?, and where the stock could go from here in the CSAN stock forecast.

For income investors, whether CSAN pays a dividend and how the payout looks is covered in does CSAN pay a dividend? And to weigh CSAN against a peer, read the full side-by-side comparisons: CSAN vs SHEL and CSAN vs COMP.